相关实验视频

Updated: Sep 11, 2025

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

长期全闭与远端扩散性疾病的PCI:单独使用支架与支架加药气球相比

Xinyi Yan^1,2, Xinchen Gao^1,2, Yingying Hu^1,2

¹Department of Cardiology, Zhongnan Hospital of Wuhan University, Wuhan 430062, China.

International journal of cardiology. Heart & vasculature

|August 13, 2025

概括

将药物排泄支架 (DES) 与药物涂层气球 (DCB) 血管整形相结合,可显著降低复杂冠状动脉疾病患者的主要不良心血管事件和住院病例. 这种策略提供了一个优越的选择,在慢性完全封闭复血管化后管理扩散性病变.

科学领域:

心脏病学心脏病学
干预心脏病学干预心脏病学
血管医学血管医学

背景情况:

慢性全闭症 (CTO) 在皮肤冠状动脉干预 (PCI) 中带来了挑战.
扩散冠状动脉病变PCI后增加了复缩风险,并需要复杂的支架.
管理扩散性疾病的CTO需要有效的重血管化策略.

研究的目的:

为了比较DES加DCB血管整形与仅DES治疗的临床结果.
评估联合DES和DCB在复血管化CTO与扩散性冠状动脉疾病中的疗效.
评估对主要不良心血管事件 (MACE) 和症状改善的影响.

主要方法:

一项对重血管化的CTO和扩散性病变患者的比较研究.
有两个组:仅DES (n=191) 和DES加DCB (n=100).
主要终点:MACE (所有原因死亡,心脏死亡,中风,再血管化). 二级终点:心血管住院和症状改善 (CCS分类).

主要成果:

DES加DCB组的MACE发病率显著降低 (26.0%与41.4%,P=0.008).
在DES加DCB组中,与心血管相关的住院治疗减少了 (20.0%对36.7%,P=0.005).
加拿大心血管学会 (CCS) 的改善分类对DES加DCB (P < 0.001) 更为显著,被确定为对MACE (HR,0.57) 的保护性.

结论:

联合DES加DCB策略与CTO患有扩散冠状动脉疾病的患者的更好的临床结果有关.
与仅使用DES相比,这种方法导致MACE降低,心血管住院减少.
在复杂的冠状动脉病变中,DES加DCB血管造形术代表了一个潜在的优越治疗选择.

关键词:

首席技术官 (CTO) 负责这些事情.在 DCB DCB 的位置上.在 DES DES 中,您可以使用马子马子马子重新血管化的治疗方法

更多相关视频

Imaging In-Stent Restenosis: An Inexpensive, Reliable, and Rapid Preclinical Model

Imaging In-Stent Restenosis: An Inexpensive, Reliable, and Rapid Preclinical Model

Published on: September 14, 2009

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis

Published on: August 26, 2025

相关概念视频

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...

Coronary Artery Disease V: Interprofessional Care

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...